Commercialization teams are doing the right activities, but they are not always doing them together, according to our Commercialization That Works research findings reported in the 2026 Biopharma Commercialization Research Report.
The cost of that misalignment across commercialization functions shows up in responsiveness. What is missing is the wiring between the recommendation and the action.
This is not a data problem in the traditional sense but a decisioning problem. It is the breakdown of cohesion in what our Commercialization That Works research identified as the “last operational mile.ˮ
When operational gaps exist in the insight-to-action loop
What breaks today:
-
Fragmented systems impede the one source of truth.
-
Vital context for real-time decisions is missing.
-
The moment for action passes due to disconnects between the analytics and execution layers.
-
Every event triggers a sequence of meetings instead of action.
-
Actions require a hand-off that adds a week to the timeline.
Diagnosing where it breaks down
Based on our experience, every real-time commercialization decision across launch, established brand, and access scenarios needs to pass through 5 consequential checkpoints:
A failure at any one of these inhibits timely execution, and most leaders can name the checkpoint where their organization breaks down the moment they see the list. The next step is asking why it breaks there and what sequence of fixes addresses it.
The structural obstacles often emerge where strategy, teams, tech, and data intersect, and the pattern is easiest to see in the scenarios that commercialization teams live every week.
Read the whitepaper that steps through the 5 checkpoints, including why they break, how that shows up, and what can be done about it.